Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has shared an update.
JCR Pharmaceuticals has issued a partial correction to its previously disclosed consolidated financial results for the three months ended June 30, 2025, after identifying errors in the original document. The company stated that certain numerical figures have been amended and that the updated data will be formally resubmitted, but stressed that its full-year financial and dividend forecasts remain unchanged.
For the first quarter of fiscal 2025, JCR reported net sales of ¥8.57 billion, up 5.2% year on year, while recording an operating loss of ¥606 million and a net loss attributable to shareholders of ¥546 million, reflecting continued investment and pressure on profitability. Despite a modest decline in the equity ratio, management is maintaining guidance for the year ending March 31, 2026, projecting a return to profit with ¥37.8 billion in net sales and ¥3.0 billion in net income, a stance that provides some visibility for investors amid near-term losses.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on developing therapies that address rare diseases and other complex healthcare challenges. The company leverages proprietary technologies and scientific expertise to market approved treatments in Japan for growth disorders, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia, while advancing a pipeline of investigational drugs for multiple lysosomal storage and rare syndromes worldwide.
Headquartered in Japan and listed on the Tokyo Stock Exchange, JCR is expanding its presence into the U.S., Europe, and Latin America as it builds on a 50-year legacy in biopharmaceutical innovation. Its strategy emphasizes next-generation therapies for underserved patient populations, aligning with core values that prioritize patients, partnerships, and global medical advancement across its specialty markets.
Average Trading Volume: 551,901
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen69.05B
Find detailed analytics on 4552 stock on TipRanks’ Stock Analysis page.